Review process
Identify New Agents
CDP is proactively seeking new agents to bring back into clinical development from leading pharmaceutical and biotechnology companies. Discussions are currently underway with a number of key players in the industry who have identified agents that may be suitable for CDP.
Companies may also contact CDP directly at enquiries@clinicalpartnerships.com
CDP Review
Agents identified from initial company discussions will be evaluated by the CDP team. A thorough technical and commercial review will be conducted including where appropriate, evaluation by the CDP Scientific Advisory Board (SAB). Processes are in place to ensure the evaluation is conducted swiftly and feedback provided as early as possible.
NAC Review
An application with a proposed trial outline will be submitted to the New Agents Committee (NAC) for review and funding approval. Either a preliminary or full proposal will be submitted depending on the stage of development of the agent and quantity of information available. The application will be prepared by CDP in consultation with the company and/or a nominated clinician as appropriate.
